Outlook Therapeutics (OTLK) Gains from Sales and Divestitures: 2018-2020
- Outlook Therapeutics' Gains from Sales and Divestitures was N/A to $109 in Q2 2020 from the same period last year, while for Jun 2020 it was $109, marking a year-over-year change of. This contributed to the annual value of $4,069 for FY2019, which is 96.14% down from last year.
- According to the latest figures from Q2 2020, Outlook Therapeutics' Gains from Sales and Divestitures is $109, which was down 0.00% from $109 recorded in Q1 2020.
- Outlook Therapeutics' 5-year Gains from Sales and Divestitures high stood at $105,361 for Q3 2018, and its period low was $109 during Q4 2019.
- Over the past 3 years, Outlook Therapeutics' median Gains from Sales and Divestitures value was $109 (recorded in 2020), while the average stood at $21,951.
- Data for Outlook Therapeutics' Gains from Sales and Divestitures shows a maximum YoY slumped of 96.14% (in 2019) over the last 5 years.
- Over the past 3 years, Outlook Therapeutics' Gains from Sales and Divestitures (Quarterly) stood at $105,361 in 2018, then crashed by 96.14% to $109 in 2019, then reached $109 in 2020.
- Its Gains from Sales and Divestitures was $109 in Q2 2020, compared to $109 in Q1 2020 and $109 in Q4 2019.
